OncoBeta® chosen as a 2019 Red Herring Top 100 Europe Winner
Recognition of OncoBeta's success in developing and providing an innovative therapy for patients suffering from non-melanocytic skin cancer
By: OncoBeta GmbH
Red Herring Top 100 Europe enlists outstanding entrepreneurs and promising companies. It selects the award winners from approximately 1,200 privately financed companies each year in the European Region. Since 1996, Red Herring has kept tabs on these up-and-comers. Red Herring's Top 100 list has become a mark of distinction for identifying promising new companies and entrepreneurs. Red Herring's editors were among the first to recognize that companies such as Alibaba, Facebook, Google, SalesForce.com, Skype, SuperCell, Spotify, Twitter, and YouTube would change the way we live and work. Thousands of the most interesting and innovative companies have graced the Top 100 list over the years.
"In 2019, selecting the top achievers was by no means a small feat," said Alex Vieux, publisher and CEO of Red Herring. "In fact, we had the toughest time in years because so many entrepreneurs had crossed significant milestones so early in the European tech ecosystem. But after much thought, rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across Europe to the Top 100 Winners. We believe OncoBeta® embodies the vision, drive and innovation that define a successful entrepreneurial venture. OncoBeta® should be proud of its accomplishment, as the competition was very strong."
"We are extremely excited and very honored to be recognized as a Red Herring Award Winner. It acknowledges our successful work as a pioneer and innovator in the epidermal radioisotope therapy sector. We have developed and provide a completely new and innovative treatment for non-melanocytic skin cancer (NMSC), the world's most common cancer," states Shannon D. Brown III, CEO of OncoBeta. "Our flagship product the Rhenium-SCT®
Red Herring's editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technological innovation, management quality, overall business strategy and market penetration. This assessment was complemented by a review of the track records and standings of similar startups in the same verticals, allowing Red Herring to see past the "hype" and make the list a valuable instrument of discovery and advocacy for the most promising new business models in Europe.
About the Rhenium-SCT®
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-
Find out more about the Rhenium-SCT®
Follow us on social media:
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®'s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®'s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
85748 Garching bei München, GERMANY